0RKL logo

Xvivo Perfusion LSE:0RKL Stock Report

Last Price

kr354.75

Market Cap

kr11.2b

7D

12.1%

1Y

16.1%

Updated

26 Apr, 2024

Data

Company Financials +

Xvivo Perfusion AB (publ)

LSE:0RKL Stock Report

Market Cap: kr11.2b

0RKL Stock Overview

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania.

0RKL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Xvivo Perfusion AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xvivo Perfusion
Historical stock prices
Current Share Pricekr354.75
52 Week Highkr381.50
52 Week Lowkr205.50
Beta2.09
1 Month Change29.00%
3 Month Change22.97%
1 Year Change16.13%
3 Year Change3.88%
5 Year Change99.75%
Change since IPO293.08%

Recent News & Updates

Recent updates

Shareholder Returns

0RKLGB Medical EquipmentGB Market
7D12.1%-1.1%2.2%
1Y16.1%-11.3%0.9%

Return vs Industry: 0RKL exceeded the UK Medical Equipment industry which returned -11.3% over the past year.

Return vs Market: 0RKL exceeded the UK Market which returned 0.9% over the past year.

Price Volatility

Is 0RKL's price volatile compared to industry and market?
0RKL volatility
0RKL Average Weekly Movement7.5%
Medical Equipment Industry Average Movement8.3%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0RKL's share price has been volatile over the past 3 months.

Volatility Over Time: 0RKL's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
1998160Christoffer Rosenbladwww.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.

Xvivo Perfusion AB (publ) Fundamentals Summary

How do Xvivo Perfusion's earnings and revenue compare to its market cap?
0RKL fundamental statistics
Market capkr11.23b
Earnings (TTM)kr100.43m
Revenue (TTM)kr642.95m

111.8x

P/E Ratio

17.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RKL income statement (TTM)
Revenuekr642.95m
Cost of Revenuekr167.55m
Gross Profitkr475.40m
Other Expenseskr374.97m
Earningskr100.43m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 12, 2024

Earnings per share (EPS)3.19
Gross Margin73.94%
Net Profit Margin15.62%
Debt/Equity Ratio0%

How did 0RKL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.